Prostate cancer theranostics using GRPR antagonist RM26
, 2019 The malignant transformation of cells is often associated with an alteration of their molecular phenotype, resulting in overexpression of several cell surface proteins. Gastrin-releasing peptide receptor (GRPR) and prostate-specific membrane antigen (PSMA) are examples of such pro-teins that are expressed at a high density in prostate cancer.
openaire +1 more source
Preclinical Evaluation of a <sup>177</sup>Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with Everolimus. [PDF]
ACS Pharmacol Transl SciKumar N +8 more
europepmc +1 more source
Prostate Cancer Imaging Beyond PSMA: Applications of GRPR, AR, and Amino Acid Tracers. [PDF]
Diagnostics (Basel)Ali FZ.
europepmc +1 more source
In vivo gastrin releasing peptide receptor expression in SDH deficient wild-type gastrointestinal stromal tumours (GIST): potential for theranostic applications. [PDF]
EJNMMI ResHulse DGE +12 more
europepmc +1 more source
Molecular targets and the emerging role of copper radionuclides in prostate cancer theranostics. [PDF]
EJNMMI ResRodrigues D +4 more
europepmc +1 more source
Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions. [PDF]
Eur J Nucl Med Mol ImagingVirgolini IJ, Di Santo G, Santo G.
europepmc +1 more source
Recent Advances in Radiopharmaceuticals for Cancer Diagnosis and Therapy. [PDF]
Oncol ResHan YR, Lee SB.
europepmc +1 more source
Studies on the impact of modifications at the Gln-Trp site in RM2-based GRPR ligands. [PDF]
EJNMMI ResFischer S +5 more
europepmc +1 more source
Advances in molecular imaging: diagnostic, technical, and therapeutic considerations-introductory Editorial. [PDF]
Br J RadiolVeit-Haibach P, Nanni C.
europepmc +1 more source
Gastrin-releasing peptide receptor (GRPR; GRP-R) [PDF]
Science-Business eXchange, 2009 openaire +1 more source